Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Intranasal Esketamine in Healthy Asian and Caucasian Subjects
NCT02846519Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2016
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of esketamine in major depressive disorder (MDD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration, Time to Reach Maximum Observed Plasma Concentration and 2 more. Started Feb 2016; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02846519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02846519.